Markers in Nonalcoholic Steatohepatitis

Basit Öğe Kaydı
dc.contributor.authorArmutcu, Ferah
dc.contributor.authorAkyol, Sumeyya
dc.contributor.authorUcar, Fatma
dc.contributor.authorErdogan, Serpil
dc.contributor.authorAkyol, Omer
dc.date.accessioned2025-10-24T18:08:53Z
dc.date.available2025-10-24T18:08:53Z
dc.date.issued2013
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractNonalcoholic fatty liver disease (NAFLD), the most common liver disorder worldwide, encompasses a spectrum of abnormal liver histology ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. Population studies show that NAFLD is strongly associated with insulin resistance, obesity, type 2 diabetes mellitus, and lipid abnormalities. In the context of hepatic steatosis, factors that promote cell injury, inflammation, and fibrosis include oxidative stress, early mitochondrial dysfunction, endoplasmic reticulum stress, iron accumulation, apoptosis, adipocytokines, and stellate cell activation. The exact NASH prevalence is unknown because of the absence of simple noninvasive diagnostic tests. Although liver biopsy is the gold standard for the diagnosis of NASH, other tests are needed to facilitate the diagnosis and greatly reduce the requirement for invasive liver biopsy. In addition, the development of new fibrosis markers in NASH is needed to facilitate the assessment of its progression and the effectiveness of new therapies. The aim of this chapter, which is overview of biomarkers in NASH, is to establish a systematic approach to laboratory findings of the disease.
dc.identifier.doi10.1016/B978-0-12-407680-8.00004-X
dc.identifier.endpage125
dc.identifier.isbn978-0-12-407827-7
dc.identifier.isbn978-0-12-407680-8
dc.identifier.issn0065-2423
dc.identifier.pmid24015600
dc.identifier.scopus2-s2.0-84878657108
dc.identifier.scopusqualityQ1
dc.identifier.startpage67
dc.identifier.urihttps://doi.org/10.1016/B978-0-12-407680-8.00004-X
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3364
dc.identifier.volume61
dc.identifier.wosWOS:000320925300004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Academic Press Inc
dc.relation.ispartofAdvances In Clinical Chemistry, Vol 61
dc.relation.publicationcategoryKitap Bölümü - Uluslararası
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectFatty Liver-Disease; Chronic Hepatitis-C; Nf-Kappa-B; Inflammatory Cytokine Levels; Induced Insulin-Resistance; Stress-Related Parameters; Simple Noninvasive Index; Chronic Viral-Hepatitis; Tumor-Necrosis-Factor; Oxidative Dna-Damage
dc.titleMarkers in Nonalcoholic Steatohepatitis
dc.typeBook Chapter

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu